TG Therapeutics (NASDAQ:TGTX) reported first-quarter 2026 results that management characterized as “record-setting” across ...
Q1 updated the commercial trajectory relative to Q4’s outlook: Q4 guidance was "$825 million to $850 million" for 2026 U.S. BRIUMVI net revenue, while Q1 said, "we're raising full year U.S. revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results